Insider Selling: Merck & Co., Inc. (NYSE:MRK) EVP Sells $788,799.00 in Stock

Merck & Co., Inc. (NYSE:MRK) EVP Richard Deluca sold 6,050 shares of the business’s stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $130.38, for a total transaction of $788,799.00. Following the transaction, the executive vice president directly owned 155,487 shares in the company, valued at $20,272,395.06. This trade represents a 3.75% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $133.10 on Thursday. The company has a debt-to-equity ratio of 1.02, a current ratio of 1.30 and a quick ratio of 1.06. Merck & Co., Inc. has a one year low of $77.58 and a one year high of $135.05. The company has a fifty day moving average price of $124.94 and a 200 day moving average price of $119.64. The stock has a market cap of $328.38 billion, a P/E ratio of 106.48, a PEG ratio of 5.62 and a beta of 0.19.

Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The company had revenue of $16.61 billion for the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.05%. The business’s quarterly revenue was up 5.1% on a year-over-year basis. During the same period last year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts anticipate that Merck & Co., Inc. will post 2.77 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be paid a dividend of $0.85 per share. This represents a $3.40 annualized dividend and a yield of 2.6%. The ex-dividend date is Tuesday, September 15th. Merck & Co., Inc.’s payout ratio is currently 272.00%.

Trending Headlines about Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst sentiment improved: Daiwa Securities upgraded Merck to “outperform” and set a $143 price target, while Argus raised its target to $145 and maintained a “buy” rating. These targets imply additional upside from recent trading levels. Daiwa Securities upgrade
• Positive Sentiment: RSV expansion opportunity: The FDA and European Medicines Agency accepted supplemental applications for broader use of ENFLONSIA to prevent RSV in vulnerable young children. The regulatory reviews could expand Merck’s growth beyond oncology and help diversify the portfolio ahead of Keytruda’s future patent expirations. Merck RSV regulatory review article
• Positive Sentiment: Estimates edged higher: Erste Group raised its FY2026 earnings forecast for Merck to $2.75 per share from $2.70, broadly aligning with the $2.76 consensus estimate. The company also recently exceeded quarterly revenue and adjusted earnings expectations, reporting $16.61 billion in revenue.
• Positive Sentiment: Core business remains solid: Keytruda, oncology and animal health supported quarterly growth, while the company continues investing in its pipeline. Merck also declared its regular $0.85 quarterly dividend, equivalent to a $3.40 annualized payout.
• Neutral Sentiment: Vaccine-policy uncertainty: Reports that the administration may seek to split the MMR vaccine into separate shots could create headlines around the broader vaccine market, but experts say the proposal lacks scientific support and is unlikely to advance. MMR vaccine policy article
• Negative Sentiment: Repeated insider selling: EVP Richard R. Deluca sold roughly 45,000 shares across transactions from August 6 through August 12 for approximately $6.7 million. Although he retained a substantial position, the sales may weigh modestly on sentiment.
• Negative Sentiment: Longer-term risks persist: Analysts continue to flag falling estimates, a high valuation and upcoming patent expirations, particularly the eventual loss of Keytruda exclusivity. These issues could limit upside unless Merck’s pipeline and newer products offset the expected revenue pressure.

Hedge Funds Weigh In On Merck & Co., Inc.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kingdom Financial Group LLC. bought a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $25,000. Abound Financial LLC bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. Prosperity Bancshares Inc bought a new stake in Merck & Co., Inc. during the 4th quarter worth approximately $26,000. High Note Wealth LLC increased its holdings in Merck & Co., Inc. by 58.9% during the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares in the last quarter. Finally, IFC & Insurance Marketing Inc. acquired a new stake in Merck & Co., Inc. during the 4th quarter valued at $31,000. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts have recently weighed in on the company. Weiss Ratings lowered Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a report on Tuesday. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Royal Bank Of Canada reissued an “outperform” rating and issued a $142.00 target price on shares of Merck & Co., Inc. in a research note on Wednesday, July 8th. BMO Capital Markets increased their price target on shares of Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company lifted their price objective on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Fifteen equities research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company’s stock. According to data from MarketBeat.com, Merck & Co., Inc. presently has a consensus rating of “Moderate Buy” and an average price target of $135.50.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.